Head-To-Head Analysis: Alseres Pharmaceuticals (OTCMKTS:ALSE) & Marker Therapeutics (NASDAQ:MRKR)

Marker Therapeutics (NASDAQ:MRKR) and Alseres Pharmaceuticals (OTCMKTS:ALSE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Profitability

This table compares Marker Therapeutics and Alseres Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Alseres Pharmaceuticals	N/A	N/A	N/A

Insider and Institutional Ownership

22.4% of Marker Therapeutics shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 8.9% of Alseres Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Marker Therapeutics and Alseres Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55 million	6.90	-$12.16 million	($0.61)	-2.41
Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Alseres Pharmaceuticals has lower revenue, but higher earnings than Marker Therapeutics.

Analyst Recommendations

This is a summary of current ratings and price targets for Marker Therapeutics and Alseres Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1	1	2	0	2.25
Alseres Pharmaceuticals	0	0	0	0	0.00

Marker Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 580.27%. Given Marker Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Marker Therapeutics is more favorable than Alseres Pharmaceuticals.

Summary

Marker Therapeutics beats Alseres Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.